2024-05-01 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 |
2024-04-24 16:30 | UU:SMMT | | News Release200 | Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 |
2024-04-11 16:30 | UU:SMMT | | News Release200 | Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors |
2024-04-10 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum |
2024-03-22 07:00 | UU:SMMT | | News Release200 | Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 |
2024-03-14 07:00 | UU:SMMT | | News Release200 | Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 |
2024-03-05 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference |
2024-02-20 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 |
2024-02-14 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics to Host Fourth Quarter & Full Year 2023 |
2024-02-07 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics to Present at Oppenheimer ¢ € ™s 34th Annual Healthcare Life Sciences Conference |
2024-01-08 09:00 | UU:SMMT | | News Release200 | Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference |
2024-01-03 07:30 | UU:SMMT | | News Release200 | Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference |
2023-11-07 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 |
2023-11-02 16:41 | UU:SMMT | | News Release200 | Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development |
2023-10-31 08:00 | UU:SMMT | | News Release200 | Ivonescimab ¢ € ™s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023 |
2023-10-26 08:00 | UU:SMMT | | News Release200 | Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023 |
2023-10-19 08:00 | UU:SMMT | | News Release200 | H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development |
2023-10-16 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer |
2023-08-09 07:00 | UU:SMMT | | News Release200 | Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023 |
2023-08-02 08:00 | UU:SMMT | | News Release200 | Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023 |
2023-06-04 08:00 | UU:SMMT | | News Release200 | Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023 |
2023-06-01 07:30 | UU:SMMT | | News Release200 | Ivonescimab Updated Data to be Featured at ASCO 2023 |
2023-05-11 07:30 | UU:SMMT | | News Release200 | Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023 |
2023-05-09 07:30 | UU:SMMT | | News Release200 | Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112) |